# A Paris Laboratory Found That CBD Blocks HIV in Human Tissue. It Is Not a Prevention Strategy.

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cbd-and-hiv-transmission-preclinical-evidence/
> **Published:** 2026-09-13T10:54:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:49-04:00
> **Clinical Summary:** A preclinical study connects CBD and HIV transmission through TRPV1 signaling in human tissue. No human trials exist and nothing about PrEP changes.

---

CED Clinical Relevance #58Mechanistic Interest, Not Clinical GuidancePatients will encounter headlines about this paper and some will misread them as evidence that CBD offers protection against HIV. Clinicians need an accurate account of what was and was not demonstrated, because the cost of an overstated claim here is measured in infections.

A team in Paris reported that cannabidiol blocks HIV-1 from infecting the immune cells that the virus uses to establish a foothold, and that it does so in donated human foreskin tissue as well as in culture. The mechanism is coherent and the work is careful. There are no human trials, no dosing data, and no evidence that any CBD product on the market provides protection against HIV.

Clinical Insight | CED Clinic

Researchers at Institut Cochin in Paris reported in *Mucosal Immunology* that cannabidiol inhibits HIV-1 infection of mucosal target cells in culture, acting through the TRPV1 ion channel rather than through CB1 or CB2 receptors. In human inner foreskin tissue studied outside the body, cannabidiol blocked early transmission events, specifically the formation of Langerhans cell to T-cell conjugates and the CD4 T-cell infection that follows.

This is laboratory and ex vivo work. There were no human participants, no clinical outcomes, no pharmacokinetic data for cannabidiol at genital mucosa, and no comparison against established pre-exposure prophylaxis. Nothing in this paper supports using cannabidiol to reduce HIV risk, and the authors do not claim otherwise.

CannabidiolHIV ResearchTRPV1 PathwayPreclinical ScienceEvidence Literacy
AudienceClinicians, researchers, and informed patientsPrimary TopicPreclinical evidence on cannabidiol and mucosal HIV-1 transmissionSource[Read the full source](https://doi.org/10.1016/j.mucimm.2026.03.006)
Why This Matters

The phrase the authors use in their own conclusion, CBD PrEP, is going to travel further than the data behind it. It appears in the paper as a proposal for future investigation, framed around the idea that commercially available cannabidiol products might eventually be repositioned. Between that proposal and a usable prevention product sits a research program that has not started.

For clinicians, the useful content is mechanistic rather than practical. This work places cannabidiol inside a neuroimmune signaling pathway that has little to do with the cannabinoid receptors most practitioners associate with the compound. That is worth understanding on its own terms, and it is worth being able to explain to a patient who arrives with a headline.

What the Researchers Did

The paper, *Cannabidiol prevents mucosal HIV-1 transmission by targeting Langerhans cells, dendritic cells, macrophages and T-cells*, was published in *Mucosal Immunology* on April 7, 2026. The first author is Caio Cesar Barbosa Bomfim and the senior author is Yonatan Ganor, both at the Laboratory of Mucosal Entry, Persistence and Neuro-Immune Control of HIV-1 and Other Viruses at Institut Cochin, a joint unit of Universite Paris Cite, INSERM, and CNRS. Coauthors include Morgane Bomsel at Cochin, Isabelle Matias and Daniela Cota at the Neurocentre Magendie in Bordeaux, and urologists Nicolas Barry Delongchamps and Marc Zerbib, whose department supplied the human tissue.

Sexual transmission of HIV-1 depends on what happens in the first hours at a mucosal surface. The virus can infect CD4 T-cells or macrophages directly, and it can also be handed off indirectly, carried by Langerhans cells or dendritic cells to CD4 T-cells. The Cochin group had previously shown that the neuropeptide CGRP, calcitonin gene-related peptide, inhibits Langerhans cell mediated transfer of HIV-1, and that CGRP release in those cells follows activation of the TRPV1 ion channel.

Cannabidiol activates TRPV1 more readily than it activates CB1 or CB2. That pharmacology is what prompted the question the paper asks: if TRPV1 activation drives CGRP release, and CGRP interferes with viral transfer, does cannabidiol do the same thing?

What They Found, Stated Precisely

In culture, cannabidiol inhibited direct HIV-1 infection of macrophages and of CD4 T-cells, and it inhibited CD4 T-cell infection that occurred after viral transfer from Langerhans cells and dendritic cells. The authors attribute this activity to TRPV1 activation. For two of those effects, inhibition of macrophage infection and inhibition of Langerhans cell mediated transfer, they report that secreted CGRP is involved.

In human inner foreskin tissue studied outside the body, cannabidiol blocked early transmission events. The specific readouts were the formation of epidermal Langerhans cell to T-cell conjugates, the physical contacts through which the virus is passed, and the CD4 T-cell infection that results from them. Working in donated human tissue rather than in a cell line is a meaningful methodological step, because it preserves some of the architecture of the surface where transmission actually begins.

The authors summarize their result as cannabidiol inhibiting infection of all HIV-1 cellular targets, and they close by proposing that commercial cannabidiol products might be repositioned as a novel form of pre-exposure prophylaxis, which they call CBD PrEP. That proposal is a stated direction for research. The paper contains no data on whether it would work in a person.

What This Is Not

This study involved no human participants. There was no trial, no exposure, no infection endpoint, and no comparison against tenofovir-based oral prophylaxis or long-acting injectable cabotegravir, both of which have large randomized trials behind them and prevent HIV acquisition effectively when taken as prescribed.

The work does not establish what concentration of cannabidiol reached the relevant cells, what concentration a person could achieve at genital mucosa with any available product, or how long any effect would last. Concentrations that work in a dish are frequently unreachable in living tissue. Ex vivo tissue also lacks blood flow, systemic immune traffic, semen, vaginal or rectal fluid, coinfection, and inflammation, all of which shape transmission in reality.

One transmission route was modeled, using inner foreskin tissue. Vaginal, rectal, and other mucosal surfaces differ in epithelial structure and immune cell composition, and nothing here speaks to them. The single most important thing a clinician can say about this paper is that no cannabidiol product available anywhere has been shown to reduce a person’s risk of acquiring HIV, and no one should alter a prevention plan because of it.

Why TRPV1 Is the Interesting Part

TRPV1 is not a cannabinoid receptor. It is the transient receptor potential vanilloid 1 channel, best known as the sensor that makes capsaicin burn, and it sits on peripheral sensory nerve endings and on some immune cells. It has a long-established role in pain signaling and neurogenic inflammation.

The chain this paper describes runs from a plant compound to an ion channel on a sensory pathway, to release of a neuropeptide, to interference with how a virus moves between immune cells. That is a nervous system and immune system conversation, and cannabidiol appears able to start it. Whatever happens to the HIV question, that pathway is a real contribution to understanding what cannabidiol does in tissue.

It also complicates the common shorthand that cannabidiol acts on the endocannabinoid system. Much of its measurable activity happens at targets outside CB1 and CB2, and this paper is a clean example. Clinicians who describe cannabidiol to patients purely in terms of cannabinoid receptors are describing a smaller compound than the one in the literature.

What Would Have to Happen Next

Moving from this paper toward anything clinical would require, at minimum, dose response work in tissue models across multiple mucosal sites, formulation and pharmacokinetic studies establishing what concentration a topical product delivers to the relevant cell layers, animal challenge studies, local safety and tolerability data for cannabidiol applied to genital mucosa, and only then early phase human trials.

There is also a question the paper does not raise. Cannabidiol has documented immunosuppressive properties, and the authors note this in their framing. A compound that dampens local immune activity at a mucosal surface is not obviously a safe thing to apply repeatedly there, and the net effect on susceptibility to HIV or to other sexually transmitted infections would need direct study rather than assumption.

None of that research exists yet. A realistic timeline for answering the question is measured in years, and most preclinical findings of this kind do not survive the trip.

Study SnapshotStudy TypePreclinical: in vitro primary human cell culture plus ex vivo human tissueInstitutionsInstitut Cochin, Universite Paris Cite, INSERM U1016, CNRS UMR8104; Neurocentre Magendie, University of Bordeaux; Urology Service, GH Cochin-St Vincent de PaulHuman ParticipantsNone. No clinical outcomes were measuredCell Targets StudiedLangerhans cells, dendritic cells, macrophages, CD4-positive T-cellsTissue ModelEx vivo human inner foreskin, modeling one mucosal transmission routeProposed MechanismCannabidiol activates TRPV1 rather than CB1 or CB2; CGRP release is implicated in the effect on macrophage infection and on Langerhans cell mediated viral transferEx Vivo ResultBlocked early transmission events: formation of epidermal Langerhans cell to T-cell conjugates and the resulting CD4 T-cell infectionAuthors’ ProposalThat commercial cannabidiol products might be repositioned as HIV-1 pre-exposure prophylaxis, termed CBD PrEP. Presented as a direction for researchPrimary LimitationNo human trials, no dosing or pharmacokinetic data, single mucosal site, no comparison with established prophylaxisJournalMucosal Immunology, 2026;19(3):100332PMID / DOI42014233 / 10.1016/j.mucimm.2026.03.006
How Strong Is This Evidence?

Within preclinical immunology, this is good work. It uses primary human cells rather than immortalized lines, tests several distinct cell populations, probes mechanism by blocking CGRP to check pathway dependence, and validates in donated human tissue. It also fits coherently into a research program the same laboratory has been building for more than a decade around CGRP, TRPV1, and mucosal HIV entry.

Preclinical evidence and clinical evidence are different categories, not different points on one scale. This paper provides no information about whether cannabidiol reduces HIV acquisition in a human being, because it was not designed to and could not. The appropriate ceiling on interpretation is that a plausible mechanism has been described in human cells and tissue.

Where This Paper Deserves Skepticism

The concentrations at which cannabidiol produced these effects in culture are the first thing that will matter in any follow-up, and there is no evidence that a topical product could achieve them in the relevant cell layers of living mucosa. Preclinical antiviral findings routinely collapse at this step.

Ex vivo tissue is a stronger model than a cell line and a much weaker model than a person. It has no circulation, no systemic immune traffic, no genital secretions, no concurrent infection or inflammation, and no repeated exposure. Each of those changes transmission biology.

The framing of cannabidiol as immunosuppressive sits uneasily beside the proposal to apply it to mucosal tissue for prevention. Local immune suppression at a portal of entry is a plausible route to increased susceptibility, and that possibility has not been tested here.

The CBD PrEP phrase, appearing in the abstract of a paper with no human data, invites exactly the misreading that makes this topic risky. The naming is the authors’ choice and the coverage that follows is predictable.

What This Paper Does Not Show

This study does not show that cannabidiol prevents HIV infection in people. It does not show that any commercially available CBD oil, cream, lubricant, or edible reduces HIV risk by any amount.

It does not establish an effective dose, a formulation, a duration of protection, or a route of application. It does not compare cannabidiol with tenofovir-based oral prophylaxis or long-acting injectable cabotegravir, which do prevent HIV acquisition and which remain the correct answer for anyone seeking prevention.

It does not demonstrate that people who use cannabidiol have lower rates of HIV acquisition, and it does not show that patients living with HIV who use cannabidiol for symptom relief are receiving any HIV-specific benefit from it.

How This Fits With the Broader Clinical Conversation

Cannabinoid biology keeps producing findings that sit outside the receptors the field is named after. Cannabidiol has documented activity at TRPV1, GPR55, adenosine reuptake, and several enzyme systems, and its effects in the clinic have rarely mapped cleanly onto CB1 or CB2 occupancy. This paper is another entry in that pattern rather than an exception to it.

It also lands in a prevention field that has genuinely effective tools and a distribution problem. Oral and long-acting injectable prophylaxis work; reaching the people who need them does not happen reliably. The appeal of a cheap, widely available topical agent is obvious, and that appeal is precisely why claims in this space need to be held to a strict standard before they reach patients.

Dr. Caplan’s Take

The part of this paper I find genuinely interesting is the route. Not CB1, not CB2, but TRPV1, the same channel that makes chili peppers burn, sitting at an intersection of pain signaling, neurogenic inflammation, and apparently mucosal antiviral defense. The chain from a plant molecule to an ion channel to a neuropeptide to a virus’s ability to move between immune cells is a real piece of biology, and it is the kind of finding that expands the map of what this compound touches.

The part that concerns me is what happens to this study between the journal and a patient’s phone. A headline that reads CBD blocks HIV is three clicks and no lies away from a person deciding they can skip prophylaxis. That is not a hypothetical failure mode. It is the ordinary path a preclinical finding takes through social media, and the harm would be permanent.

So when someone brings this to me, I say two things and I say them together. This is careful science from a serious laboratory showing a plausible mechanism in human tissue, and it deserves funding and follow-up. It is not a reason to change anything about how you protect yourself, today or next year. Both of those are true and neither one cancels the other.

Clinical Bottom Line

Cannabidiol interferes with HIV-1 infection of mucosal immune cells in the laboratory, apparently through TRPV1 and CGRP signaling, and the effect held up in donated human tissue. There is no human evidence of any kind. Anyone seeking HIV prevention should use the methods with randomized trial support, and clinicians should expect patient questions about this paper and answer them clearly.

What a Careful Reader Should Take Away

Carry forward the mechanism: cannabidiol acts at TRPV1, TRPV1 activation releases CGRP, and CGRP interferes with how HIV-1 moves between mucosal immune cells. Leave behind any version of the sentence CBD prevents HIV. The study documents a pathway in cells and tissue. Prevention is a claim about people, and this work contains no people.

Evidence Interpretation Guide

Table of Contents

- [How to read a preclinical antiviral finding without misreading it](#How_to_read_a_preclinical_antiviral_finding_without_misreading_it)
- [Cannabidiol and HIV-1, Seen From Eight Angles](#Cannabidiol_and_HIV-1_Seen_From_Eight_Angles)[This changes nothing about how to protect yourself](#This_changes_nothing_about_how_to_protect_yourself)
- [Expect the question and answer it in one sentence](#Expect_the_question_and_answer_it_in_one_sentence)
- [The concentration problem](#The_concentration_problem)
- [What the design can and cannot support](#What_the_design_can_and_cannot_support)
- [A decade of CGRP work stands behind this](#A_decade_of_CGRP_work_stands_behind_this)
- [Nothing here translates into a product](#Nothing_here_translates_into_a_product)
- [The research program that does not yet exist](#The_research_program_that_does_not_yet_exist)
- [Why naming matters in prevention science](#Why_naming_matters_in_prevention_science)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to read a preclinical antiviral finding without misreading it

The Research QuestionDoes cannabidiol, acting through TRPV1 and CGRP, inhibit HIV-1 infection of the mucosal immune cells the virus uses to establish infection?The Patient QuestionDoes taking or applying CBD protect me from HIV?The Bottom LineIn cells and donated human tissue, yes, cannabidiol interfered with infection. In people, unknown and untested. The answer to the patient question today is no.
CED Perspective Lens

## Cannabidiol and HIV-1, Seen From Eight Angles

One preclinical paper, read through the lenses that keep a finding in proportion.

Lens OverviewA Paris laboratory reported that cannabidiol, acting at TRPV1 rather than at cannabinoid receptors, inhibited HIV-1 infection of macrophages, CD4 T-cells, Langerhans cells and dendritic cells, and blocked early transmission events in donated human foreskin tissue. No human trials have been conducted.

#### This changes nothing about how to protect yourself

If you use cannabidiol, this study does not mean you have any protection against HIV. The work was done in cells and in donated tissue in a laboratory. No person has ever been studied to see whether cannabidiol reduces the chance of acquiring HIV, and no product on any shelf has been tested for that purpose.

Prevention methods that have been tested in people, including daily oral prophylaxis and long-acting injectable prophylaxis, work when used as prescribed. If you are trying to reduce your risk, those are the options to discuss with a clinician.

Lens takeawayInteresting science. Not protection. Do not change your prevention plan.

#### Expect the question and answer it in one sentence

Patients who follow cannabis research will bring this paper in, and the version they encountered probably carried the phrase CBD PrEP. A short, direct answer works better than a hedge: this was a laboratory study with no human participants, and cannabidiol has never been tested for HIV prevention in people.

The follow-on conversation is worth having. Patients living with HIV who use cannabidiol for nausea, pain, or sleep should understand that any benefit they get is symptomatic, and that cannabidiol interacts with a number of medications through CYP pathways, which matters in the context of antiretroviral regimens.

Lens takeawayAnswer plainly, then review interactions with the patient’s actual medication list.

#### The concentration problem

Antiviral effects observed in culture depend on concentrations chosen by the investigator, and the gap between those concentrations and what a living tissue can achieve is where most preclinical antivirals die. This paper does not address what a topical cannabidiol product would deliver to epidermal Langerhans cells in vivo.

There is a second tension. Cannabidiol is described in the paper’s own framing as having well-documented immunosuppressive functions. Applying an immunosuppressant to a mucosal surface as a prevention strategy is not self-evidently safe, and the net effect on susceptibility is unstudied.

Lens takeawayUnknown achievable dose plus unstudied local immunosuppression is a wide gap to close.

#### What the design can and cannot support

Primary human cells and donated human tissue are appropriate models for asking whether a mechanism exists. They are not models for asking whether an intervention works. The distinction is categorical, and no amount of methodological care within the preclinical design converts one into the other.

The mechanism itself is also reported at different levels of resolution for different cell types. CGRP involvement is described for macrophage infection and for Langerhans cell mediated transfer. How the effect is produced in the other target populations is less fully specified in the abstract, and readers should not assume a single uniform pathway.

Lens takeawayCite this for mechanism in human cells, never for efficacy in humans.

#### A decade of CGRP work stands behind this

The same laboratory previously showed that CGRP inhibits Langerhans cell mediated HIV-1 transfer and that CGRP release in those cells follows TRPV1 activation. This paper extends that line by asking whether cannabidiol, a known TRPV1 agonist, can trigger the same protective cascade.

That continuity matters when judging credibility. The finding is not an isolated screening hit. It is the predicted next step in an established mechanistic program, which makes it more likely to be real and no more likely to be clinically useful.

Lens takeawayA coherent research program raises confidence in the mechanism, not in the application.

#### Nothing here translates into a product

There is no cannabidiol formulation designed or validated for mucosal application in this context. Commercial CBD products vary widely in actual cannabinoid content, and many contain carriers, preservatives, or flavorings that have not been evaluated for genital or rectal mucosal safety.

Improvised use carries real risks independent of HIV: mucosal irritation, disruption of epithelial integrity, and incompatibility with condoms depending on the base. Oil-based products degrade latex, which would reduce the effectiveness of a prevention method that does work.

Lens takeawayImprovising a topical from a retail CBD product could increase risk rather than lower it.

#### The research program that does not yet exist

A credible path forward runs through dose response work across multiple mucosal tissue types, formulation and pharmacokinetic studies establishing achievable local concentrations, animal challenge studies, local safety and tolerability data, and then early phase human trials in people at elevated risk.

That is a multi-year program and none of it has been reported. Until at least the pharmacokinetic step is answered, the honest status of CBD PrEP is a hypothesis with a name.

Lens takeawayThe next meaningful milestone is pharmacokinetic, not clinical.

#### Why naming matters in prevention science

Attaching the term PrEP to a preclinical finding borrows the credibility of an established prevention category. PrEP means something specific to clinicians and to people at risk: a regimen with randomized evidence of efficacy. Applying the word to an untested compound blurs a distinction that public health communication depends on.

The underlying motivation is real. Access to existing prophylaxis is uneven, and a low-cost, shelf-stable option would matter. That is an argument for funding the research properly, not for loosening the language while it is pending.

Lens takeawayAccess gaps justify investment in research, not premature use of prevention vocabulary.
Related Reading at CED ClinicContinue exploring the evidence[THC vs CBD vs CBG vs CBN vs THCV: The Real Differences Explained](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/)

Background on why cannabidiol’s activity extends well past CB1 and CB2, which is the pharmacology this study turns on.

[Compare the cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/)[Neuroinflammation and the Glial Endocannabinoid System](https://cedclinic.com/neuroinflammation-and-the-glial-endocannabinoid-system/)

More on the neuroimmune signaling territory where cannabinoids, sensory channels, and immune cells interact.

[Read the mechanism review](https://cedclinic.com/neuroinflammation-and-the-glial-endocannabinoid-system/)[High-Dose CBD for Neuropathic Pain After Spinal Cord Injury](https://cedclinic.com/high-dose-cbd-neuropathic-pain-spinal-cord-injury/)

A useful contrast: what cannabidiol evidence looks like once it reaches a randomized trial in people.

[See the clinical trial](https://cedclinic.com/high-dose-cbd-neuropathic-pain-spinal-cord-injury/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Does CBD prevent HIV?

No. A 2026 study in Mucosal Immunology found that cannabidiol inhibited HIV-1 infection of immune cells in laboratory culture and blocked early transmission events in donated human tissue. That work involved no human participants and measured no clinical outcomes. No cannabidiol product has been shown to reduce a person’s risk of acquiring HIV. Established prevention methods with randomized trial evidence remain the correct choice.

What did the CBD and HIV study actually find?

Working in primary human cells, researchers at Institut Cochin in Paris reported that cannabidiol inhibited direct HIV-1 infection of macrophages and CD4 T-cells, and inhibited CD4 T-cell infection following viral transfer from Langerhans cells and dendritic cells. In donated human inner foreskin tissue, cannabidiol blocked the formation of Langerhans cell to T-cell contacts and the CD4 T-cell infection that follows from them.

What is TRPV1 and why does it matter here?

TRPV1 is the transient receptor potential vanilloid 1 ion channel, best known as the sensor that makes capsaicin feel hot. It sits on sensory nerve endings and on some immune cells. Cannabidiol activates TRPV1 more readily than it activates CB1 or CB2. In this study, TRPV1 activation was the proposed entry point for the antiviral effect, with release of the neuropeptide CGRP implicated in part of it.

What is CBD PrEP?

It is a phrase the study authors used in their own conclusion, proposing that commercially available cannabidiol products might eventually be repositioned as a form of HIV pre-exposure prophylaxis. It describes a direction for future research, not an existing intervention. No formulation, dose, or route has been established, and no clinical trial has been conducted. The term borrows a word that normally signals randomized evidence.

Is the study reliable?

Within its scope it is careful work. It used primary human cells rather than immortalized cell lines, examined four distinct target populations, tested pathway dependence by blocking CGRP, and validated findings in donated human tissue. It also builds on more than a decade of work by the same laboratory on CGRP and mucosal HIV entry. Being methodologically sound and being clinically applicable are separate questions, and only the first applies here.

Should people living with HIV who use CBD expect any benefit against the virus?

No. Cannabidiol used for nausea, pain, or sleep is providing symptom relief, and nothing in this study indicates it affects viral control or transmission in a person. Cannabidiol also interacts with several drug-metabolizing enzymes, which is clinically relevant for anyone on an antiretroviral regimen. Anyone using cannabidiol alongside HIV medication should have those interactions reviewed by a clinician or pharmacist.

Could someone apply a CBD product topically for protection?

That would be unwise. No product has been tested for mucosal application in this context, commercial cannabidiol products vary widely in actual content, and carriers and additives have not been evaluated for genital or rectal mucosal safety. Oil-based products also degrade latex, which can compromise condoms. Improvising a topical from a retail product could raise risk rather than lower it.

What research would be needed before this could change practice?

Dose response studies across multiple mucosal tissue types, formulation and pharmacokinetic work establishing what concentration reaches the relevant cells in living tissue, animal challenge studies, local safety and tolerability data for mucosal application, and then early phase human trials in people at elevated risk. None of that has been reported. A realistic timeline runs to years, and most preclinical findings do not survive it.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).